Research programme: anti-infectives - GlycoMimetics
Alternative Names: Carbohydrate mimics for bacterial infections - GlycoMimetics; GMI-1051Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator GlycoMimetics
- Class Small molecules
- Mechanism of Action Lectin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pseudomonal infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pseudomonal-infections in USA
- 08 Sep 2014 Pharmacodynamics data from preclinical studies in pseudomonal infections released by GlycoMimetics
- 03 Aug 2006 GMI 1051 has been selected as lead candidate for the treatment of Pseudomonal infections